Similarly, the overexpression of GGPS1, GART, and HMGCS1 reduced the overall survival duration in patients with glioblastoma, ovarian cancer, and endometrial cancer but not in those with prostate cancer (Supplementary Figure S10). This evidence concerns the gene HMGCS1 and prostate carcinoma.